Boston area  startups Cocoon Biotech, Riparian Pharmaceuticals, Cellanyx Diagnostics, and DavosPharma  were awarded$22K in funds and in-kind services at an innovation competition held by Biotech Tuesday, a Cambridge-based networking organization for life science professionals.

left-to-right : Execs from EMD Serono, Novartis and Lab Central

At an event on November 19th event, executives from EMD Serono, Novartis Institutes for BioMedical Research and LabCentral chose the winning startup pitches from among five finalists’ presentations. The finalists were selected from an initial field of thirteen online entries based, in part, on online feedback from BiotechTuesday members. The three winners were all therapeutics and diagnostics startups proposing solutions to challenging medical problems.

Cocoon Biotech, Inc., led by CEO and founder Ailis Tweed-Kent, a doctor at Massachusetts General Hospital won the $5000 EMD Serono Innovation Award.  Cocoon Biotech is developing a silk-based gel for injection into the joint to provide long lasting joint support and lubrication in patients with osteoarthritis.  EMD Serono is the biopharmaceutical subsidiary of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical group.

Riparian Pharmaceuticals, led by Will Adam, Chief Scientific Officer and President, won both the $10,000 in-kind Novartis Innovation Award and the $3000 in-kind Pharmatek Innovation Award. Riparian Pharmaceuticals is focused on therapeutics that induce an anti-inflammatory response in cells to address diseases such as atherosclerosis.  Novartis Institutes for BioMedical Research, Inc. discovers and develops new and innovative medicines. Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development and manufacturing organization supporting the pharmaceutical & biotechnology industries.

Cellanyx Diagnostics, led by Co-Founder and CEO Ashok Chander, won the $4000 in-kind LabCentral Innovation Award.  Cellanyx is developing a prostate cancer diagnostic based on culturing tumor biopsy cells that promises to be much more accurate than current diagnostics.  LabCentral provides fully functional lab space, permits, waste handling, plus all reasonably common lab equipment for bioresearch.

In addition to awarding startups, the event also acknowledged the contribution of life science products and services in enabling cutting edge research for new therapeutics.  DavosPharma won the Most Innovative Product or Service Award in recognition of its Anthem-GenTox product. This product offers scientists a high throughput genotoxicity assay based on human cells with greatly improved accuracy over conventional methods.

“This was Biotech Tuesday’s first innovation competition–but by no means its last, “said BioTechTuesday Co-Founder Seth Taylor, who organizes BiotechTuesday and served as master of ceremonies for the event.” The feedback from attendees was overwhelmingly in favor of the competition,” Taylor said.  “We look forward to continuing our efforts to engage our broad community of life science professionals in supporting innovators.”

The competition took place at District Hall, a new event space at 75 Northern Avenue in the Boston Seaport District.

–Anita Harris

Anita Harris is a writer and content expert based in Cambridge, MA. 

New Cambridge Observer is published by the Harris Communications Group,  a PR and marketing firm based at the Cambridge Innovation Center, in Kendall Square. HarrisCom offers writing and content services for clients in healthcare, life sciences, biotech, energy and the environment.  Full disclosure:  HarrisCom handled media outreach for the event as a probono sponsor. 

Our colleague Seth Taylor asked us to let you know that BioTechTuesday will be holding a $22K Life Science Innovation Competition and Pitch event on November 19; deadline to enter the competition is Tuesday, Nov. 12.

Here’s the scoop:

BiotechTuesday, a networking organization for life science professionals, will hold an innovation competition at which major pharmaceutical and biotechnology companies will award $22K in funds and in-kind services.   The winners will be life-science startups and researchers judged to have the most innovative ideas and laboratory products.

The event will take place at District Hall, a new event space at 75 Northern Avenue in the Boston Seaport District, from 6-9, on Tuesday, November 19.

Awards include:

• Financial and in-kind prizes for the most promising startup concepts and early stage ventures. Innovators can submit their concept or venture online for consideration by November 12, 2013. The BiotechTuesday community will then vote online—contributing to the selection of five finalists who will pitch their concepts at the event. At the event, competition judges from Novartis, EMD Serono, Pharmatek and others, will choose the winners.  CLICK HERE TO ENTER[http://goo.gl/gBhiaq]

• Recognition for the most innovative recently-launched products or services. Companies can submit recently launched products or services online for consideration, by November 12, 2013.  Finalists will present their pitches one-on-one to attendees and judges at the event.  CLICK HERE TO ENTER [http://goo.gl/03Q7pG]

“This competition event is unique in that it relies on a true community from a top life-science super cluster to select and validate some of the most exciting new approaches in the field,” said Seth Taylor, BiotechTuesday co-founder and host. “It provides a tremendous opportunity for the community to engage with innovators launching the hot companies of the future, and products that may impact their work today.”

Peter Parker, co-founder and director of programming for LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences startups, said: “We share in Biotech Tuesday’s mission to advance innovation in the life-sciences community. We are pleased to offer one month’s free membership and a bench space in LabCentral’s co-working lab and office facility ($4,000 value). LabCentral provides fully functional lab space, permits, waste handling, plus all reasonably common lab equipment for bioresearch. Access to conference rooms and event space,  kitchens, etc. is also included, as is participation in programming specific to the interests of life-sciences startups.”

In the words of Charles Wilson, Vice President and Head of Business at Novartis Institutes for Biomedical Research, Inc:  “We believe that the time and expertise of large companies can be of great value to startups.  For this reason, we have committed to offering resources and analysis to help a winning company reach investors and commercialize their therapeutics.”

Timothy Scott, President and Co-Founder, Pharmatek Inc., a contract research organization offering $3000 in reagents to the winning team, said:  “We are committed to supporting innovation with our products and services, and through our Pharmatek University educational programs,”

Event attendance is open to the public. Click here to register [http://goo.gl/fRUh1J].

BioTechTuesday is a networking organization offering monthly events and an online community for life science professionals.  Founded in 2002 in the Boston area, BiotechTuesday now has thousands of members. 

Contact: Seth Taylor 617-615-6152    staylor@biotechtuesday.com   Twitter: #pitchbio

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning PR and market development firm specializing in strategic communication, media relations, social and digital media for health care, life science, biotech, tech and energy.  

UK-based Alacrita, a global life science consulting firm with consultants worldwide, will soon be opening an office in Cambridge, MA, according to Robert Johnson, who will head the office, here.

The company was co-founded two years ago by Anthony Walker, who had previously served as Executive Director of Global External R&D Europe at Eli Lilly,  and  by Johnson, who had led business development at Onyvax, a biotech company that developed biopharmaceuticals to combat cancer.

Drawing on the capabilities of more than 50 consultants worldwide, Alacrita  provides strategic, operational,  technical  advice or  hands-on project management to organizations of all sizes in  the pharma, biotechnology and life science industries, Johnson said.

According to the Alacrita Web site, clients may be academic institutes, tech transfer experts,  life science investors, startups  or  established companies in need of expertise in:

• Business development and marketing
• Intellectual property
• Product development
• Regulatory affairs

Recent whitepapers available on the  company Website   include:

• Biotech in Israel: A Land of Promise » May 2012 – by Anthony Walker, PhD
• FDA Approvals Provide Reason For Cheer » March 2012 – by Robert Johnson
• Deal Watch Annual Review 2011 » January 2012
• Viewpoint: Pharma Industry Myths » January 2012 – by Anthony Walker, PhD
• Europe’s stellar decade of prostate cancer innovation » September 2011 – by Rob Johnson
• Are we all biotech now? » June 2011 – by Anthony Walker and Rob Johnson
• China: Opportunities for biotech firms » March 2011 – by Rob Johnson and Li Zeng
• Re-Profiling: a Hidden Threat to Originators? » February 2011 – by Dr Jo Davies
• Deal Watch Annual Review 2010 » January 2011 – by Roger Davies and Jill Ogden
• Mitigating Out-sourcing Risk » December 2010 – by Robert Johnson and Anthony Walker
• Deal Watch: a Review of Notable Deals » October 2010 – by Sharon Finch

Alacrita’s US offices will be located in the Cambridge Innovation Center in Kendall Square.  The company name comes from the Latin, “alacritas,” or “lively.”  It is meant to convey “a cheerful readiness,” Johnson said.

–Anita M. Harris

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning strategic public relations,  marketing communications and thought leadership firm in Cambridge, MA.

SHANAHAN NAMED VP OF BUSINESS DEVELOPMENT

—One of the newest international companies to expand into Cambridge is Ariana (R)  Pharma–a 2003 spin-out of the Pasteur Institute in Paris.  Its  subsidiary, Ariana Data Intelligence, Inc., located in the Cambridge Innovation Center at 1 Broadway,  will provide novel non-statistical clinical data analysis technology to pharma and the FDA,  Ariana announced today.

The technology,  “Knowledge Extraction and Management Technology (KEM)” is aimed at reducing cost, bias, and risk in clinical trials.

“The US pharma and biotech markets tend  to be early technology adopters and are searching for better data analytics tools to advance personalized medicine using all the new biomarker, genomic, proteomic and metabolomic data now being generated,” said  Dr. Mohammad Afshar, Ariana’s President and CEO.

KEM   “is the only FDA-tested technology that  can simultaneously analyze all these variables and pull out patient responder sub-groups, optimize biomarker signatures and remove bias from clinical trials,” Afshar said.

A “unique” association rules-based (non-statistical) analytical technology, KEM  finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect, according to Afshar.  KEM thus optimizes clinical trial inclusion/exclusion criteria, thereby lowering the number of patients needed to reach clinical endpoints and saving sponsors both time and cash, and reducing clinical drug development risk.

In conjunction with the opening, Ariana has appointed James M. Shanahan as Vice President  of Business Development.  Shanahan was previously a co-founder and is currently a  board member of SynDevRx, Inc., an oncology-focused biotech company. He was also a co-founder and VP Corporate Development of JAM Technologies, Inc.

Ariana offers something “special and desperately needed “by the pharmaceutical industry, Shanahan said.   “Companies spend tens of millions generating data.  Now, it’s all about making sense of that data.  KEM identifies useful, complex biological relationships that statistics routinely miss.”

More information is available at  http://www.arianapharma.com/  .

–Anita M. Harris